1. Home
  2. VALN
  3. VALN News

Latest Valneva SE (VALN) News on February 22, 2025

Valneva hits 2024 sales target but plans lower cash burn in 2025
VALN

Pharmaceutical Technology

4 days ago

Valneva hits 2024 sales target but plans lower cash burn in 2025

Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook
VALN

GlobeNewswire

4 days ago

Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook

Bavarian Nordic scoops FDA approval for chikungunya vaccine in adults and teens
VALN

Pharmaceutical Technology

5 days ago

Bavarian Nordic scoops FDA approval for chikungunya vaccine in adults and teens

Shareholding declaration Valneva SE - January 2025
VALN

GlobeNewswire

16 days ago

Shareholding declaration Valneva SE - January 2025

Valneva’s chikungunya vaccine wins UK approval
VALN

Pharmaceutical Technology

17 days ago

Valneva’s chikungunya vaccine wins UK approval

VALN

MT Newswires

17 days ago

Valneva Gets Marketing Authorization in UK for Chikungunya Vaccine; Shares Rise

Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ®
VALN

GlobeNewswire

17 days ago

Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ®

VALN

MT Newswires

23 days ago

Valneva Signs $33 Million Ixiaro Vaccine Supply Contract With US Defense Department; Shares Climb

Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million
VALN

GlobeNewswire

23 days ago

Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million

Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision
VALN

GlobeNewswire

a month ago

Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision

High Growth Tech Stocks To Watch In January 2025
VALN

Simply Wall St.

a month ago

High Growth Tech Stocks To Watch In January 2025

Valneva announces positive outcomes from chikungunya vaccine trial
VALN

Clinical Trials Arena

a month ago

Valneva announces positive outcomes from chikungunya vaccine trial

Favorable VLA1553-321 Phase 3 Study Results Boost VALN Stock
VALN

Zacks

a month ago

Favorable VLA1553-321 Phase 3 Study Results Boost VALN Stock

Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine
VALN

GlobeNewswire

a month ago

Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference
VALN

GlobeNewswire

2 months ago

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference

VALNEVA Declaration of shares and voting rights: December 31, 2024
VALN

GlobeNewswire

2 months ago

VALNEVA Declaration of shares and voting rights: December 31, 2024

Exploring High Growth Tech Stocks for December 2024
VALN

Simply Wall St.

2 months ago

Exploring High Growth Tech Stocks for December 2024

Valneva and Serum Institute of India Collaborate to Tackle Chikungunya in Asia
VALN

TipRanks

2 months ago

Valneva and Serum Institute of India Collaborate to Tackle Chikungunya in Asia

Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India
VALN

GlobeNewswire

2 months ago

Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India

VALNEVA - Declaration of shares and voting rights: November 30, 2024
VALN

GlobeNewswire

3 months ago

VALNEVA - Declaration of shares and voting rights: November 30, 2024

Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal
VALN

GlobeNewswire

3 months ago

Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal

Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®
VALN

GlobeNewswire

3 months ago

Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®

Chikungunya Vaccine Label Extension Call Likely to Support VALN Stock
VALN

Zacks

3 months ago

Chikungunya Vaccine Label Extension Call Likely to Support VALN Stock

VALN

MT Newswires

3 months ago

Valneva Submits Label Extension Application to US FDA for Chikungunya Vaccine IXCHIQ

Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA
VALN

GlobeNewswire

3 months ago

Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA

High Growth Tech Stocks To Explore This November 2024
VALN

Simply Wall St.

3 months ago

High Growth Tech Stocks To Explore This November 2024

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department
VALN

The Wall Street Journal

3 months ago

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2
VALN

GlobeNewswire

3 months ago

Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
VALN

GlobeNewswire

3 months ago

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

Valneva SE (INRLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved ...
VALN

GuruFocus.com

3 months ago

Valneva SE (INRLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved ...

Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates
VALN

GlobeNewswire

3 months ago

Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates

Valneva SE (VALN) Q3 2024 Earnings Report Preview: What to Look For
VALN

GuruFocus.com

4 months ago

Valneva SE (VALN) Q3 2024 Earnings Report Preview: What to Look For

VALNEVA - Declaration of shares and voting rights: October 31, 2024
VALN

GlobeNewswire

4 months ago

VALNEVA - Declaration of shares and voting rights: October 31, 2024

High Growth Tech Stocks in France to Watch October 2024
VALN

Simply Wall St.

4 months ago

High Growth Tech Stocks in France to Watch October 2024

Lectra And 2 Other High Growth Tech Stocks In France
VALN

Simply Wall St.

4 months ago

Lectra And 2 Other High Growth Tech Stocks In France

Exploring 3 High Growth Tech Stocks In France
VALN

Simply Wall St.

4 months ago

Exploring 3 High Growth Tech Stocks In France

Valneva to Present on Chikungunya at Several Leading Scientific Conferences
VALN

GlobeNewswire

4 months ago

Valneva to Present on Chikungunya at Several Leading Scientific Conferences

High Growth Tech Stocks In France Featuring 3 Promising Companies
VALN

Simply Wall St.

4 months ago

High Growth Tech Stocks In France Featuring 3 Promising Companies

VALN

MT Newswires

4 months ago

Valneva, LimmaTech Get FDA Fast Track Designation for Shigellosis Vaccine Candidate

Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V
VALN

GlobeNewswire

4 months ago

Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V

High Growth Tech Stocks In France October 2024
VALN

Simply Wall St.

4 months ago

High Growth Tech Stocks In France October 2024

Valneva Hosts Investor Day in New York City
VALN

GlobeNewswire

4 months ago

Valneva Hosts Investor Day in New York City

Valneva SE (INRLF) (H1 2024) Earnings Call Highlights: Navigating Growth Amidst Revenue Challenges
VALN

GuruFocus.com

4 months ago

Valneva SE (INRLF) (H1 2024) Earnings Call Highlights: Navigating Growth Amidst Revenue Challenges

Exclusive Networks And 2 High Growth Tech Stocks In France
VALN

Simply Wall St.

4 months ago

Exclusive Networks And 2 High Growth Tech Stocks In France

Exploring Three High Growth Tech Stocks in France
VALN

Simply Wall St.

4 months ago

Exploring Three High Growth Tech Stocks in France

Valneva SE - Declaration of shares and voting rights - September 30, 2024
VALN

GlobeNewswire

5 months ago

Valneva SE - Declaration of shares and voting rights - September 30, 2024

Valneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET
VALN

GlobeNewswire

5 months ago

Valneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET

Valneva eyes teenage label for chikungunya vaccine in Europe and Canada
VALN

Pharmaceutical Technology

5 months ago

Valneva eyes teenage label for chikungunya vaccine in Europe and Canada

Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada
VALN

GlobeNewswire

5 months ago

Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada

Valneva Announces the Success of its Private Placement Raising approximately €60 Million
VALN

GlobeNewswire

5 months ago

Valneva Announces the Success of its Private Placement Raising approximately €60 Million

Valneva Announces the Launch of a Private Placement of Ordinary Shares for Approximately 60 Million Euros
VALN

GlobeNewswire

5 months ago

Valneva Announces the Launch of a Private Placement of Ordinary Shares for Approximately 60 Million Euros

Esker And 2 Other High Growth Tech Stocks In France
VALN

Simply Wall St.

5 months ago

Esker And 2 Other High Growth Tech Stocks In France

VALNEVA - Declaration of shares and voting rights: August 31, 2024
VALN

GlobeNewswire

6 months ago

VALNEVA - Declaration of shares and voting rights: August 31, 2024

Pfizer And Valneva Partnered Lyme Disease Vaccine Shows Effectiveness As Booster Shot In Mid-Stage Study
VALN

Benzinga

6 months ago

Pfizer And Valneva Partnered Lyme Disease Vaccine Shows Effectiveness As Booster Shot In Mid-Stage Study

Favorable VLA15 Phase 2 Study Results Might Boost VALN Stock
VALN

Zacks

6 months ago

Favorable VLA15 Phase 2 Study Results Might Boost VALN Stock

Valneva and Pfizer report positive data from trial of Lyme disease vaccine booster
VALN

Clinical Trials Arena

6 months ago

Valneva and Pfizer report positive data from trial of Lyme disease vaccine booster

Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate
VALN

GlobeNewswire

6 months ago

Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

Wall Street Analysts Predict a 150.41% Upside in Valneva (VALN): Here's What You Should Know
VALN

Zacks

6 months ago

Wall Street Analysts Predict a 150.41% Upside in Valneva (VALN): Here's What You Should Know

High Growth Tech Stocks in France Featuring Lectra and Two More
VALN

Simply Wall St.

6 months ago

High Growth Tech Stocks in France Featuring Lectra and Two More

How Much Upside is Left in Valneva (VALN)? Wall Street Analysts Think 135.3%
VALN

Zacks

6 months ago

How Much Upside is Left in Valneva (VALN)? Wall Street Analysts Think 135.3%

Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates
VALN

GlobeNewswire

6 months ago

Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates

VALNEVA - Declaration of shares and voting rights: July 31, 2024
VALN

GlobeNewswire

7 months ago

VALNEVA - Declaration of shares and voting rights: July 31, 2024

Valneva and LimmaTech partner for shigellosis vaccine development
VALN

Pharmaceutical Technology

7 months ago

Valneva and LimmaTech partner for shigellosis vaccine development

Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate
VALN

GlobeNewswire

7 months ago

Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate

Can Valneva (VALN) Climb 149.04% to Reach the Level Wall Street Analysts Expect?
VALN

Zacks

7 months ago

Can Valneva (VALN) Climb 149.04% to Reach the Level Wall Street Analysts Expect?

Valneva and CEPI expand deal for chikungunya vaccine trials
VALN

Clinical Trials Arena

7 months ago

Valneva and CEPI expand deal for chikungunya vaccine trials

CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine
VALN

GlobeNewswire

7 months ago

CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine

Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026
VALN

Benzinga

7 months ago

Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026

Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion
VALN

GlobeNewswire

7 months ago

Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion

Valneva (VALN) Gets EC's Approval on Chikungunya Vaccine
VALN

Zacks

7 months ago

Valneva (VALN) Gets EC's Approval on Chikungunya Vaccine

Declaration of shares and voting rights - Valneva SE - June 30, 2024
VALN

GlobeNewswire

8 months ago

Declaration of shares and voting rights - Valneva SE - June 30, 2024

VALN

MT Newswires

8 months ago

Valneva's Secures Marketing Authorization in Europe for Chikungunya Vaccine

Valneva’s chikungunya vaccine gains EC’s market authorisation
VALN

Pharmaceutical Technology

8 months ago

Valneva’s chikungunya vaccine gains EC’s market authorisation

Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ®
VALN

GlobeNewswire

8 months ago

Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ®

Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board
VALN

GlobeNewswire

8 months ago

Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board

Valneva's (VALN) CHIKV Vaccine Gets Health Canada's Approval
VALN

Zacks

8 months ago

Valneva's (VALN) CHIKV Vaccine Gets Health Canada's Approval

VALN

MT Newswires

8 months ago

Valneva's Chikungunya Vaccine Receives Health Canada's Approval

Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ®
VALN

GlobeNewswire

8 months ago

Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ®

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update
VALN

GlobeNewswire

9 months ago

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

VALNEVA - Declaration of shares and voting rights: May 31, 2024
VALN

GlobeNewswire

9 months ago

VALNEVA - Declaration of shares and voting rights: May 31, 2024

Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June
VALN

GlobeNewswire

9 months ago

Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June

Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
VALN

GlobeNewswire

9 months ago

Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases

VALN

MT Newswires

9 months ago

Valneva's Chikungunya Vaccine Gains Support From EU Regulator Committee

Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine
VALN

GlobeNewswire

9 months ago

Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine

Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer
VALN

GlobeNewswire

9 months ago

Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer

Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine
VALN

GlobeNewswire

9 months ago

Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine

Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
VALN

GlobeNewswire

10 months ago

Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Declaration of shares and voting rights April 30, 2024 - VALNEVA SE
VALN

GlobeNewswire

10 months ago

Declaration of shares and voting rights April 30, 2024 - VALNEVA SE

Declaration of voting rights - Valneva SE, March 2024
VALN

GlobeNewswire

a year ago

Declaration of voting rights - Valneva SE, March 2024

Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
VALN

GlobeNewswire

a year ago

Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
VALN

GlobeNewswire

a year ago

Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F

Valneva SE (NASDAQ:VALN) Q4 2023 Earnings Call Transcript
VALN

Insider Monkey

a year ago

Valneva SE (NASDAQ:VALN) Q4 2023 Earnings Call Transcript

Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.
VALN

GlobeNewswire

a year ago

Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.

Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
VALN

GlobeNewswire

a year ago

Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook

Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed
VALN

GlobeNewswire

a year ago

Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed

VALNEVA Declaration of shares and voting rights - February 29, 2024
VALN

GlobeNewswire

a year ago

VALNEVA Declaration of shares and voting rights - February 29, 2024

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
VALN

GlobeNewswire

a year ago

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ®
VALN

GlobeNewswire

a year ago

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ®

Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance
VALN

GlobeNewswire

a year ago

Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance

VALNEVA: Declaration of shares and voting rights - January 31, 2024
VALN

GlobeNewswire

a year ago

VALNEVA: Declaration of shares and voting rights - January 31, 2024

Share on Social Networks: